Phase 2/3Recruiting
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
- Sponsor
- Global Coalition for Adaptive Research (Academic or other)
- Enrolment
- 2,250 planned
- Conditions
- Glioblastoma
- Interventions
- Temozolomide; Lomustine; Regorafenib; Radiation; Paxalisib; VAL-083; VT1021; Troriluzole; ADI-PEG 20; AZD1390; Tinostamustine
- Ages
- adults, older adults
- Registry
- NCT03970447
Full record on ClinicalTrials.gov
From the registry
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).
Primary outcomes
- Overall Survival (OS)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered